Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free MGRX Stock Alerts

Mangoceuticals (MGRX) Financials

Mangoceuticals logo
$0.56 +0.01 (+2.39%)
Closing price 07/28/2026 04:00 PM Eastern
Extended Trading
$0.58 +0.02 (+4.32%)
As of 07/28/2026 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Mangoceuticals

Annual Income Statements for Mangoceuticals

This table shows Mangoceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -2.00 -9.21 -9.51 -22
Consolidated Net Income / (Loss)		 -2.00 -9.21 -8.71 -21
Net Income / (Loss) Continuing Operations		 -2.00 -9.21 -8.71 -21
Total Pre-Tax Income 		-2.00 -9.21 -8.71 -21
Total Operating Income		 -1.99 -9.22 -7.97 -18
Total Gross Profit		 0.00 0.43 0.38 0.25
Total Revenue		 0.01 0.73 0.62 0.46
Operating Revenue		 0.01 0.73 0.62 0.46
Total Cost of Revenue		 0.00 1.13 1.16 1.40
Operating Cost of Revenue		 0.00 1.13 1.16 1.40
Total Operating Expenses		 2.00 8.82 8.15 18
Selling, General & Admin Expense		 1.64 3.32 3.00 3.76
Marketing Expense		 0.35 2.10 1.48 0.82
Amortization Expense		 - - 0.72 1.12
Other Operating Expenses / (Income)		 0.00 3.40 2.95 13
Total Other Income / (Expense), net		 -0.01 0.01 -0.01 -1.49
Interest Expense		 0.01 -0.01 0.01 0.12
Other Income / (Expense), net		 0.00 0.00 0.00 -1.37
Income Tax Expense		 0.00 0.00 0.00 0.00
Preferred Stock Dividends Declared		 - - 0.80 1.18
Net Income / (Loss) Attributable to Noncontrolling Interest		 - 0.00 -0.00 -0.00
Basic Earnings per Share		 ($0.19) ($8.58) ($4.80) ($2.17)
Weighted Average Basic Shares Outstanding		 10.80M 1.07M 1.98M 10.07M
Diluted Earnings per Share		 ($0.19) ($8.58) ($4.80) ($2.17)
Weighted Average Diluted Shares Outstanding		 10.80M 1.07M 1.98M 10.07M
Weighted Average Basic & Diluted Shares Outstanding		 - - 5.17M 16.97M

Quarterly Income Statements for Mangoceuticals

This table shows Mangoceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -1.80 -3.74 -2.37 -2.39 -2.29 -2.46 -5.13 -5.42 -7.91 -3.65 -3.70
Consolidated Net Income / (Loss)		 -1.80 -2.57 -2.37 -2.39 -2.00 -1.95 -4.84 -5.42 -7.62 -2.77 -3.40
Net Income / (Loss) Continuing Operations		 -1.80 -3.74 -2.37 -2.39 -2.00 -1.95 -4.84 -5.42 -7.62 -2.77 -3.40
Total Pre-Tax Income 		-1.80 -2.57 -2.37 -2.39 -2.00 -1.95 -4.84 -5.42 -7.62 -2.77 -3.40
Total Operating Income		 -1.80 -2.57 -2.37 -2.17 -1.76 -1.68 -4.58 -5.27 -7.54 -0.37 -3.13
Total Gross Profit		 0.14 0.14 0.15 0.07 0.08 0.08 0.06 0.09 0.05 0.05 0.03
Total Revenue		 0.25 0.24 0.21 0.16 0.13 0.11 0.11 0.17 0.08 0.09 0.07
Operating Revenue		 0.25 0.24 0.21 0.16 0.13 0.11 0.11 0.17 0.08 0.09 0.07
Total Cost of Revenue		 0.32 0.19 0.31 0.29 0.26 0.29 0.02 0.65 0.54 -0.44 0.01
Operating Cost of Revenue		 0.32 0.19 0.31 0.29 0.26 0.29 0.02 0.65 0.54 -0.44 0.01
Total Operating Expenses		 1.72 3.79 2.27 2.04 1.63 2.21 4.66 4.79 7.08 2.03 3.19
Selling, General & Admin Expense		 0.54 2.08 0.77 0.85 0.52 0.85 1.54 1.25 0.31 0.66 1.05
Marketing Expense		 0.72 0.30 0.85 0.23 0.25 0.15 0.28 0.26 0.10 0.18 0.09
Other Operating Expenses / (Income)		 0.46 1.42 0.64 0.96 0.85 0.49 2.84 3.29 6.67 0.07 2.04
Total Other Income / (Expense), net		 0.00 -0.01 0.00 -0.22 -0.24 0.45 -0.26 -0.15 -0.15 -1.22 -0.28
Interest Expense		 0.00 - 0.00 0.22 0.24 -0.45 -0.01 0.15 0.08 -0.09 0.00
Other Income / (Expense), net		 0.00 - 0.00 - - - -0.28 - -0.08 - -0.28
Income Tax Expense		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Preferred Stock Dividends Declared		 - - - - 0.29 - 0.29 - 0.29 - 0.29
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.00 - -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 0.00 0.00
Basic Earnings per Share		 ($1.70) ($3.48) ($1.50) ($1.37) ($1.14) ($1.24) ($1.12) ($0.57) ($0.69) ($0.36) ($0.22)
Weighted Average Basic Shares Outstanding		 1.06M 1.07M 1.57M 1.74M 2.01M 1.98M 4.59M 0.00 11.52M 10.07M 16.48M
Diluted Earnings per Share		 ($1.70) ($3.48) ($1.50) ($1.37) ($1.14) ($1.24) ($1.12) ($0.57) ($0.69) ($0.36) ($0.22)
Weighted Average Diluted Shares Outstanding		 1.06M 1.07M 1.57M 1.74M 2.01M 1.98M 4.59M 9.98M 11.52M 10.07M 16.48M
Weighted Average Basic & Diluted Shares Outstanding		 17.04M 0.00 24.82M 29.91M 2.49M 5.17M 11.03M 10.54M 13.91M 16.97M 17.17M

Annual Cash Flow Statements for Mangoceuticals

This table details how cash moves in and out of Mangoceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.66 0.06 -0.67 1.42
Net Cash From Operating Activities		 -1.35 -7.00 -4.86 -5.85
Net Cash From Continuing Operating Activities		 -1.35 -7.06 -4.86 -5.85
Net Income / (Loss) Continuing Operations		 -2.00 -9.21 -8.71 -21
Consolidated Net Income / (Loss)		 -2.00 -9.21 -8.71 -21
Depreciation Expense		 0.00 0.02 0.01 0.00
Amortization Expense		 - - 0.72 1.72
Non-Cash Adjustments To Reconcile Net Income		 0.64 2.15 2.38 13
Changes in Operating Assets and Liabilities, net		 0.01 -0.01 0.73 -0.18
Net Cash From Investing Activities		 -0.04 -0.00 0.07 0.00
Net Cash From Continuing Investing Activities		 -0.04 -0.00 0.07 0.00
Sale of Property, Plant & Equipment		 - 0.00 0.07 0.00
Net Cash From Financing Activities		 2.05 7.06 4.13 7.27
Net Cash From Continuing Financing Activities		 2.05 7.06 4.13 7.27
Repayment of Debt		 -0.03 -0.09 0.00 -0.21
Issuance of Debt		 0.08 -0.08 0.15 0.68
Issuance of Preferred Equity		 - 0.00 2.65 0.10
Issuance of Common Equity		 2.00 6.20 1.33 4.63
Other Financing Activities, net		 - 1.02 0.00 2.08
Cash Interest Paid		 0.00 0.00 0.00 0.00
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Mangoceuticals

This table details how cash moves in and out of Mangoceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -1.71 -0.50 -0.72 0.48 -0.42 -0.01 0.02 0.02 0.38 1.01 -1.31
Net Cash From Operating Activities		 -1.71 -1.70 -0.99 -1.58 -1.17 -1.13 -2.27 -1.26 -1.24 -1.08 -1.31
Net Cash From Continuing Operating Activities		 -1.71 -1.76 -0.99 -1.58 -1.17 -1.13 -2.26 -1.27 -1.24 -1.08 -1.31
Net Income / (Loss) Continuing Operations		 -1.80 -2.57 -2.37 -2.39 -2.00 -1.95 -4.84 -5.42 -7.62 -2.77 -3.40
Consolidated Net Income / (Loss)		 -1.80 -2.57 -2.37 -2.39 -2.00 -1.95 -4.84 -5.42 -7.62 -2.77 -3.40
Depreciation Expense		 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Amortization Expense		 - - - - 0.21 0.26 0.41 0.84 0.02 0.45 0.29
Non-Cash Adjustments To Reconcile Net Income		 0.15 0.79 0.45 0.85 0.64 0.44 2.00 3.24 6.74 1.27 1.70
Changes in Operating Assets and Liabilities, net		 -0.07 0.02 0.92 -0.29 -0.02 0.12 0.16 0.07 -0.38 -0.02 0.10
Net Cash From Investing Activities		 - - 0.00 0.07 - - 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 - - 0.00 0.07 - - 0.00 - - - 0.00
Net Cash From Financing Activities		 - 1.20 0.27 1.99 0.75 1.12 2.29 1.28 1.62 2.08 0.00
Net Cash From Continuing Financing Activities		 - 1.20 0.27 1.99 0.75 1.12 2.29 1.28 1.62 2.08 0.00
Issuance of Preferred Equity		 - - 0.00 1.50 0.75 0.40 1.15 -1.05 - - 0.00
Issuance of Common Equity		 - 1.20 0.18 0.39 - 0.76 0.66 0.43 1.32 2.21 0.00
Other Financing Activities, net		 - - 0.00 - - - 0.48 1.30 0.30 - 0.00
Cash Interest Paid		 - - 0.00 - - - 0.00 - - - 0.00
Cash Income Taxes Paid		 - - 0.00 - - - 0.00 - - - 0.00

Annual Balance Sheets for Mangoceuticals

This table presents Mangoceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 1.00 1.05 15 16
Total Current Assets		 0.69 0.84 0.08 1.55
Cash & Equivalents		 0.68 0.74 0.06 1.49
Accounts Receivable		 - - 0.00 0.02
Prepaid Expenses		 0.01 0.06 0.00 0.01
Other Current Assets		 - 0.02 0.02 0.03
Plant, Property, & Equipment, net		 0.12 0.10 0.00 0.00
Total Noncurrent Assets		 0.19 0.12 15 15
Intangible Assets		 - 0.00 15 14
Other Noncurrent Operating Assets		 0.19 0.12 0.06 0.31
Total Liabilities & Shareholders' Equity		 1.00 1.05 15 16
Total Liabilities		 0.39 0.28 1.43 0.89
Total Current Liabilities		 0.26 0.21 1.43 0.89
Accounts Payable		 0.03 0.14 0.84 0.42
Current Deferred & Payable Income Tax Liabilities		 0.00 - 0.00 0.01
Other Current Liabilities		 0.06 0.06 0.44 0.46
Total Noncurrent Liabilities		 0.13 0.06 0.00 0.00
Other Noncurrent Operating Liabilities		 0.13 0.06 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 0.61 0.77 14 15
Total Preferred & Common Equity		 0.61 0.77 14 15
Preferred Stock		 - 0.00 0.00 0.00
Total Common Equity		 0.61 0.77 14 15
Common Stock		 2.63 12 34 56
Retained Earnings		 -2.02 -11 -20 -41
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 -0.01 -0.00
Other Equity Adjustments		 - - 0.32 0.32
Noncontrolling Interest		 - 0.00 -0.00 -0.00

Quarterly Balance Sheets for Mangoceuticals

This table presents Mangoceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 1.60 0.30 15 15 22 21 17 14
Total Current Assets		 1.34 0.09 0.52 0.10 0.18 0.12 0.60 0.21
Cash & Equivalents		 1.24 0.02 0.49 0.07 0.08 0.10 0.48 0.17
Accounts Receivable		 - - - - - - - 0.02
Prepaid Expenses		 0.08 0.06 0.01 0.00 0.08 - 0.10 0.00
Other Current Assets		 - - - 0.02 0.02 0.02 0.02 0.02
Plant, Property, & Equipment, net		 0.10 0.09 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.15 0.12 15 15 22 21 16 14
Intangible Assets		 - - 15 15 22 21 16 14
Other Noncurrent Operating Assets		 0.15 0.12 0.11 0.07 0.04 0.03 0.01 0.29
Total Liabilities & Shareholders' Equity		 1.60 0.30 15 15 22 21 17 14
Total Liabilities		 0.24 1.26 1.41 1.40 1.50 1.60 0.80 0.97
Total Current Liabilities		 0.16 1.21 1.38 1.39 1.50 1.60 0.80 0.74
Accounts Payable		 0.09 1.05 0.72 0.75 1.18 0.77 0.53 0.53
Other Taxes Payable		 0.01 0.01 - - - - - 0.00
Other Current Liabilities		 0.06 0.07 0.47 0.44 0.33 0.20 0.17 0.20
Total Noncurrent Liabilities		 0.08 0.05 0.03 0.01 0.00 0.00 0.00 0.24
Other Noncurrent Operating Liabilities		 0.08 0.05 0.03 0.01 0.00 0.00 0.00 0.24
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1.35 -0.96 14 13 20 19 16 13
Total Preferred & Common Equity		 1.35 -0.96 14 13 20 19 16 13
Preferred Stock		 - - 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1.35 -0.96 14 13 20 19 16 13
Common Stock		 10 13 29 31 46 51 53 57
Retained Earnings		 -8.66 -14 -16 -18 -26 -32 -38 -44
Accumulated Other Comprehensive Income / (Loss)		 - -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00
Other Equity Adjustments		 - - 0.51 - 0.32 0.32 0.32 0.32
Noncontrolling Interest		 - -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00

Annual Metrics And Ratios for Mangoceuticals

This table displays calculated financial ratios and metrics derived from Mangoceuticals' official financial filings.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 17,039,500.00 2,486,512.00 13,906,570.00
DEI Adjusted Shares Outstanding		 0.00 1,135,967.00 2,486,512.00 13,906,570.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -8.11 -3.82 -1.57
Growth Metrics		 - - - -
Revenue Growth		 0.00% 8,083.16% -15.81% -25.96%
EBITDA Growth		 0.00% -362.54% 21.25% -144.09%
EBIT Growth		 0.00% -362.89% 13.53% -143.33%
NOPAT Growth		 0.00% -362.89% 13.53% -126.20%
Net Income Growth		 0.00% -361.07% 5.48% -137.08%
EPS Growth		 0.00% -361.07% 44.06% 54.79%
Operating Cash Flow Growth		 0.00% -419.66% 30.49% -20.28%
Free Cash Flow Firm Growth		 0.00% 0.00% -206.42% 37.19%
Invested Capital Growth		 0.00% -63.76% 39,164.84% -2.31%
Revenue Q/Q Growth		 0.00% 0.00% -18.43% -2.33%
EBITDA Q/Q Growth		 0.00% -41,033.18% 18.15% 0.76%
EBIT Q/Q Growth		 0.00% 0.00% 10.05% -0.29%
NOPAT Q/Q Growth		 0.00% 0.00% 10.05% 6.77%
Net Income Q/Q Growth		 0.00% 0.00% 6.64% -4.14%
EPS Q/Q Growth		 0.00% 0.00% 10.45% -26.16%
Operating Cash Flow Q/Q Growth		 0.00% -17.62% 10.46% 0.88%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.03% 20.05%
Invested Capital Q/Q Growth		 0.00% -69.72% 3.96% -10.64%
Profitability Metrics		 - - - -
Gross Margin		 54.26% 58.99% 61.70% 54.91%
EBITDA Margin		 -22,236.48% -1,256.88% -1,175.65% -3,875.64%
Operating Margin		 -22,279.70% -1,260.28% -1,294.42% -3,954.28%
EBIT Margin		 -22,279.70% -1,260.28% -1,294.42% -4,253.73%
Profit (Net Income) Margin		 -22,352.11% -1,259.40% -1,413.80% -4,526.87%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.33% 99.93% 109.22% 106.42%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -1,413.47% -9,604.58% -79.31% -90.98%
ROIC Less NNEP Spread (ROIC-NNEP)		 -1,296.29% -9,164.66% 886.27% 1,058.97%
Return on Net Nonoperating Assets (RNNOA)		 1,088.07% 8,277.89% -39.00% -50.69%
Return on Equity (ROE)		 -325.40% -1,326.69% -118.31% -141.67%
Cash Return on Invested Capital (CROIC)		 0.00% -9,510.99% -278.30% -88.64%
Operating Return on Assets (OROA)		 -198.51% -897.62% -97.09% -123.32%
Return on Assets (ROA)		 -199.15% -896.99% -106.05% -131.24%
Return on Common Equity (ROCE)		 -325.40% -1,326.69% -118.31% -141.68%
Return on Equity Simple (ROE_SIMPLE)		 -325.40% -1,189.08% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.39 -6.45 -5.58 -13
NOPAT Margin		 -15,595.79% -882.20% -906.10% -2,768.00%
Net Nonoperating Expense Percent (NNEP)		 -117.18% -439.92% -965.58% -1,149.94%
Return On Investment Capital (ROIC_SIMPLE)		 - -832.94% -39.59% -83.05%
Cost of Revenue to Revenue		 45.74% 154.86% 187.88% 307.55%
SG&A Expenses to Revenue		 18,386.53% 453.79% 487.21% 823.73%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 22,333.95% 1,205.42% 1,323.70% 3,992.92%
Earnings before Interest and Taxes (EBIT)		 -1.99 -9.22 -7.97 -19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.99 -9.19 -7.24 -18
Valuation Ratios		 - - - -
Price to Book Value (P/BV)		 8.14 6.09 0.43 0.68
Price to Tangible Book Value (P/TBV)		 8.14 6.09 0.00 10.63
Price to Revenue (P/Rev)		 559.35 6.45 9.77 22.57
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 45.47 111.31 0.44 0.64
Enterprise Value to Revenue (EV/Rev)		 501.69 5.44 9.92 19.30
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - -
Debt to Equity		 0.27 0.00 0.01 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00
Financial Leverage		 -0.84 -0.90 -0.04 -0.05
Leverage Ratio		 1.63 1.48 1.12 1.08
Compound Leverage Factor		 1.64 1.48 1.22 1.15
Debt to Total Capital		 21.43% 0.00% 1.06% 0.00%
Short-Term Debt to Total Capital		 21.43% 0.00% 1.06% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% -0.01% -0.01%
Common Equity to Total Capital		 78.57% 100.00% 98.94% 100.01%
Debt to EBITDA		 -0.08 0.00 -0.02 0.00
Net Debt to EBITDA		 0.26 0.00 -0.01 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.12 0.00 -0.03 0.00
Net Debt to NOPAT		 0.37 0.00 -0.02 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00
Altman Z-Score		 -1.13 -32.25 -1.07 -0.50
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% -0.01% -0.01%
Liquidity Ratios		 - - - -
Current Ratio		 2.67 3.96 0.05 1.74
Quick Ratio		 2.62 3.50 0.04 1.69
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -6.39 -20 -12
Operating Cash Flow to CapEx		 -3,124.03% -198,845.55% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -1,429.27 -100.07
Operating Cash Flow to Interest Expense		 -208.02 0.00 -355.02 -47.60
Operating Cash Flow Less CapEx to Interest Expense		 -214.68 0.00 -350.28 -47.60
Efficiency Ratios		 - - - -
Asset Turnover		 0.01 0.71 0.08 0.03
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.08 6.85 12.45 198.27
Accounts Payable Turnover		 0.12 12.99 2.37 2.24
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 3,005.96 28.10 154.30 163.20
Cash Conversion Cycle (CCC)		 -3,005.96 -28.10 -154.30 -163.20
Capital & Investment Metrics		 - - - -
Invested Capital		 0.10 0.04 14 14
Invested Capital Turnover		 0.09 10.89 0.09 0.03
Increase / (Decrease) in Invested Capital		 0.00 -0.06 14 -0.32
Enterprise Value (EV)		 4.48 3.98 6.11 8.80
Market Capitalization		 5.00 4.72 6.02 10
Book Value per Share		 $0.06 $0.05 $5.61 $1.09
Tangible Book Value per Share		 $0.06 $0.05 ($0.52) $0.07
Total Capital		 0.78 0.77 14 15
Total Debt		 0.17 0.00 0.15 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00
Net Debt		 -0.52 -0.74 0.09 -1.49
Capital Expenditures (CapEx)		 0.04 0.00 -0.07 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.08 -0.11 -1.26 -0.83
Debt-free Net Working Capital (DFNWC)		 0.60 0.62 -1.20 0.66
Net Working Capital (NWC)		 0.43 0.62 -1.35 0.66
Net Nonoperating Expense (NNE)		 0.60 2.76 3.13 8.02
Net Nonoperating Obligations (NNO)		 -0.52 -0.74 0.09 -1.49
Total Depreciation and Amortization (D&A)		 0.00 0.02 0.73 1.72
Debt-free, Cash-free Net Working Capital to Revenue		 -910.30% -15.68% -204.35% -181.89%
Debt-free Net Working Capital to Revenue		 6,728.81% 85.35% -194.82% 144.04%
Net Working Capital to Revenue		 4,855.44% 85.35% -219.18% 144.04%
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 $0.00 ($8.55) ($4.84) ($2.17)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 1.07M 1.98M 10.07M
Adjusted Diluted Earnings per Share		 $0.00 ($8.55) ($4.84) ($2.17)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 1.07M 1.98M 10.07M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 5.17M 16.97M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.39 -6.45 -5.58 -13
Normalized NOPAT Margin		 -15,595.79% -882.20% -906.10% -2,768.00%
Pre Tax Income Margin		 -22,352.11% -1,259.40% -1,413.80% -4,526.87%
Debt Service Ratios		 - - - -
EBIT to Interest Expense		 -307.68 0.00 -581.90 -157.83
NOPAT to Interest Expense		 -215.37 0.00 -407.33 -102.71
EBIT Less CapEx to Interest Expense		 -314.33 0.00 -577.15 -157.83
NOPAT Less CapEx to Interest Expense		 -222.03 0.00 -402.58 -102.71
Payout Ratios		 - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Mangoceuticals

This table displays calculated financial ratios and metrics derived from Mangoceuticals' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 0.00 17,039,500.00 17,039,500.00 24,819,500.00 29,905,803.00 2,486,512.00 5,168,796.00 11,034,023.00 21,071,582.00 13,906,570.00 16,967,420.00
DEI Adjusted Shares Outstanding		 0.00 1,135,967.00 1,135,967.00 1,654,633.00 1,993,720.00 2,486,512.00 5,168,796.00 11,034,023.00 21,071,582.00 13,906,570.00 16,967,420.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -3.29 -2.08 -1.45 -1.15 -0.99 -0.99 -0.49 -0.38 -0.26 -0.22
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 112.56% 15.52% -45.60% -56.93% -48.95% 3.03% -36.83% -10.34% -37.91%
EBITDA Growth		 -80.79% -66,415.20% 7.51% 4.93% 13.81% 44.56% -87.95% -104.68% -391.37% 105.66% 29.89%
EBIT Growth		 -81.43% 0.00% 7.48% 5.05% 2.30% 34.67% -104.98% -142.94% -333.36% 78.08% 29.88%
NOPAT Growth		 -81.43% 0.00% 7.48% 5.39% 2.30% 34.67% -93.29% -142.94% -329.04% 78.08% 31.69%
Net Income Growth		 -80.87% 0.00% 7.55% -4.70% -11.13% 24.12% -104.40% -126.48% -281.00% -42.12% 29.68%
EPS Growth		 -80.87% 0.00% 0.00% -4.70% -11.13% 64.37% 25.33% 58.39% 39.47% 70.97% 80.36%
Operating Cash Flow Growth		 0.00% -161.37% 45.19% 11.42% 31.85% 33.47% -129.51% 20.34% -6.47% 4.59% 42.35%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% -960.80% -774.77% -3,046.83% 34.18% 51.25% 100.44% 119.31%
Invested Capital Growth		 0.00% -63.76% 0.00% 0.00% 11,335.27% 39,164.84% 2,376.29% 45.94% 13.66% -2.31% -34.07%
Revenue Q/Q Growth		 73.58% -0.32% -12.39% -23.79% -18.26% -21.09% 3.86% 53.80% -49.89% 12.01% -28.08%
EBITDA Q/Q Growth		 21.28% -42.86% 7.82% 8.30% 28.63% 8.11% -212.51% -0.18% -71.33% 101.06% -3,969.61%
EBIT Q/Q Growth		 21.22% -42.71% 7.80% 8.40% 18.93% 4.57% -189.28% -8.86% -44.61% 95.17% -825.42%
NOPAT Q/Q Growth		 21.50% -42.71% 7.80% 8.40% 18.93% 4.57% -172.78% -8.56% -43.17% 95.12% -750.15%
Net Income Q/Q Growth		 21.22% -42.71% 7.80% -1.00% 16.38% 2.56% -148.36% -11.91% -40.68% 63.65% -22.89%
EPS Q/Q Growth		 21.22% -42.71% 7.80% -1.00% 16.38% -8.77% 9.68% 55.81% -21.05% 47.83% 38.89%
Operating Cash Flow Q/Q Growth		 3.92% 0.76% 41.62% -59.14% 26.08% 3.11% -101.38% 44.77% 1.21% 13.17% -21.67%
Free Cash Flow Firm Q/Q Growth		 0.00% -25.92% 55.55% -1,851.18% 2.86% -3.83% -59.89% 59.51% 28.05% 100.93% 6,966.20%
Invested Capital Q/Q Growth		 0.00% -69.72% -2,579.22% 1,626.25% -0.18% 3.96% 43.73% -2.15% -22.26% -10.64% -3.01%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 58.98% 58.35% 68.85% 42.77% 61.99% 76.11% 56.78% 53.51% 60.42% 50.31% 42.73%
EBITDA Margin		 -731.43% -1,048.29% -1,102.97% -1,327.16% -1,158.79% -1,349.37% -4,060.34% -2,636.54% -9,014.02% 85.22% -4,584.98%
Operating Margin		 -733.99% -1,050.87% -1,105.87% -1,329.13% -1,318.21% -1,594.02% -4,186.75% -3,133.98% -8,953.45% -389.72% -4,606.75%
EBIT Margin		 -733.99% -1,050.87% -1,105.87% -1,329.13% -1,318.21% -1,594.02% -4,440.00% -3,133.98% -9,043.49% -389.72% -5,014.65%
Profit (Net Income) Margin		 -733.99% -1,050.87% -1,105.87% -1,465.60% -1,499.38% -1,851.45% -4,427.47% -3,221.61% -9,043.49% -2,934.90% -5,014.65%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 110.27% 113.74% 116.15% 99.72% 102.80% 100.00% 753.08% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -8,008.63% 0.00% -119.24% -102.30% -97.67% -155.31% -68.06% -202.88% -8.97% -79.88%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -7,885.79% 0.00% 457.67% 34.64% 141.42% 75,921.28% -1,829.06% 1,544.45% 351.17% 887.80%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 7,122.77% 0.00% -10.02% -2.64% -6.22% -16.93% -10.85% -14.20% -16.81% -6.61%
Return on Equity (ROE)		 0.00% -885.86% 1,881.99% -129.26% -104.94% -103.89% -172.24% -78.91% -217.08% -25.78% -86.49%
Cash Return on Invested Capital (CROIC)		 0.00% -9,510.99% 0.00% -292.15% -287.63% -278.30% -139.72% -94.41% -106.65% -88.64% -28.28%
Operating Return on Assets (OROA)		 0.00% -748.46% -6,198.86% -151.21% -121.46% -119.57% -205.77% -89.65% -269.60% -11.30% -114.85%
Return on Assets (ROA)		 0.00% -748.46% -6,198.86% -166.74% -138.16% -138.88% -205.19% -92.15% -269.60% -85.08% -114.85%
Return on Common Equity (ROCE)		 0.00% -885.86% 1,881.92% -129.26% -104.70% -103.90% -172.25% -78.91% -216.84% -25.78% -86.49%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 941.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.26 -1.80 -1.66 -1.52 -1.23 -1.17 -3.20 -3.69 -5.28 -0.26 -2.19
NOPAT Margin		 -513.80% -735.61% -774.11% -930.39% -922.75% -1,115.82% -2,930.73% -2,193.78% -6,267.42% -272.80% -3,224.73%
Net Nonoperating Expense Percent (NNEP)		 -87.30% -122.83% 1,967.69% -576.91% -136.94% -239.09% -76,076.60% 1,761.00% -1,747.32% -360.14% -967.68%
Return On Investment Capital (ROIC_SIMPLE)		 - -232.03% 190.29% -10.83% -9.06% -8.33% -15.82% -18.59% -33.36% -1.69% -16.24%
Cost of Revenue to Revenue		 132.02% 76.81% 146.67% 176.98% 198.28% 275.41% 22.63% 384.96% 646.65% -467.15% 12.11%
SG&A Expenses to Revenue		 222.29% 850.14% 360.57% 521.38% 392.79% 811.48% 1,411.12% 740.81% 369.61% 696.47% 1,553.29%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 701.97% 1,552.01% 1,059.21% 1,252.14% 1,219.93% 2,104.18% 4,264.12% 2,849.01% 8,406.80% 2,146.61% 4,694.64%
Earnings before Interest and Taxes (EBIT)		 -1.80 -2.57 -2.37 -2.17 -1.76 -1.68 -4.85 -5.27 -7.62 -0.37 -3.40
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.79 -2.56 -2.36 -2.17 -1.55 -1.42 -4.44 -4.43 -7.59 0.08 -3.11
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 6.09 0.00 0.55 0.53 0.43 0.50 0.87 1.47 0.68 0.37
Price to Tangible Book Value (P/TBV)		 0.00 6.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10.63 0.00
Price to Revenue (P/Rev)		 0.00 6.45 4.37 8.70 9.35 9.77 19.72 32.50 49.42 22.57 12.08
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 111.31 0.00 0.54 0.53 0.44 0.50 0.87 1.48 0.64 0.36
Enterprise Value to Revenue (EV/Rev)		 0.00 5.44 4.46 8.36 9.50 9.92 19.57 33.47 48.60 19.30 11.65
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 -0.09 0.01 0.01 0.01 0.00 0.03 0.01 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.91 -0.90 -0.08 -0.02 -0.08 -0.04 0.00 0.01 -0.01 -0.05 -0.01
Leverage Ratio		 1.18 1.48 -0.31 1.10 1.11 1.12 1.14 1.09 1.08 1.08 1.07
Compound Leverage Factor		 1.18 1.48 -0.31 1.22 1.26 1.30 1.14 1.12 1.08 8.13 1.07
Debt to Total Capital		 0.00% 0.00% -10.05% 1.34% 1.38% 1.06% 0.00% 3.02% 0.63% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% -10.05% 1.34% 1.38% 1.06% 0.00% 3.02% 0.63% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% -0.01% -0.01% -0.01% -0.01% -0.01% -0.01% -0.01%
Common Equity to Total Capital		 100.00% 100.00% 110.04% 98.66% 98.37% 98.94% 100.01% 96.98% 99.38% 100.01% 100.01%
Debt to EBITDA		 0.00 0.00 -0.01 -0.02 -0.02 -0.02 0.00 -0.05 -0.01 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 -0.01 0.03 -0.01 -0.01 0.00 -0.04 0.02 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 -0.01 -0.03 -0.03 -0.03 0.00 -0.06 -0.01 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 -0.01 0.05 -0.02 -0.02 0.00 -0.05 0.03 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 -11.36 -88.97 1.27 0.87 0.29 1.57 3.27 12.50 3.40 -1.98
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.23% -0.01% -0.01% 0.00% 0.11% -0.01% -0.01%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 8.44 3.96 0.07 0.38 0.07 0.05 0.12 0.07 0.74 1.74 0.29
Quick Ratio		 7.77 3.50 0.01 0.36 0.05 0.04 0.05 0.06 0.60 1.69 0.26
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.38 -1.73 -0.77 -15 -15 -15 -24 -9.90 -7.12 0.07 4.69
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -67.56 -60.49 0.00 0.00 -67.21 -93.93 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 -7.08 -4.83 0.00 0.00 -8.53 -16.36 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 -7.08 -4.83 0.00 0.00 -8.53 -16.36 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.71 5.61 0.11 0.09 0.08 0.05 0.03 0.03 0.03 0.02
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 60.64 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 6.85 0.00 0.00 14.32 12.45 11.06 183.74 182.74 198.27 202.23
Accounts Payable Turnover		 0.00 12.99 0.00 0.00 2.50 2.37 0.78 2.49 3.33 2.24 1.62
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 6.02 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 28.10 0.00 0.00 145.84 154.30 468.78 146.43 109.59 163.20 224.90
Cash Conversion Cycle (CCC)		 0.00 -28.10 0.00 0.00 -139.82 -154.30 -468.78 -146.43 -109.59 -163.20 -224.90
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.12 0.04 -0.89 14 14 14 20 20 15 14 13
Invested Capital Turnover		 0.00 10.89 -1.91 0.13 0.11 0.09 0.05 0.03 0.03 0.03 0.02
Increase / (Decrease) in Invested Capital		 0.12 -0.06 -0.89 14 13 14 21 6.21 1.84 -0.32 -6.87
Enterprise Value (EV)		 0.00 3.98 3.77 7.24 7.17 6.11 10 17 23 8.80 4.83
Market Capitalization		 0.00 4.72 3.70 7.55 7.06 6.02 10 17 23 10 5.01
Book Value per Share		 $1.28 $0.05 ($0.06) $0.56 $0.45 $5.61 $3.92 $1.74 $1.49 $1.09 $0.97
Tangible Book Value per Share		 $1.28 $0.05 ($0.06) ($0.03) ($0.04) ($0.52) ($0.25) ($0.13) ($0.02) $0.07 ($0.03)
Total Capital		 1.35 0.77 -0.87 14 14 14 20 20 16 15 13
Total Debt		 0.00 0.00 0.09 0.19 0.19 0.15 0.00 0.60 0.10 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -1.24 -0.74 0.07 -0.30 0.11 0.09 -0.08 0.50 -0.38 -1.49 -0.17
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.05 -0.11 -1.05 -1.16 -1.17 -1.26 -1.40 -0.98 -0.59 -0.83 -0.70
Debt-free Net Working Capital (DFNWC)		 1.18 0.62 -1.03 -0.67 -1.10 -1.20 -1.33 -0.88 -0.11 0.66 -0.53
Net Working Capital (NWC)		 1.18 0.62 -1.12 -0.86 -1.29 -1.35 -1.33 -1.48 -0.21 0.66 -0.53
Net Nonoperating Expense (NNE)		 0.54 0.77 0.71 0.87 0.77 0.77 1.64 1.73 2.34 2.51 1.21
Net Nonoperating Obligations (NNO)		 -1.24 -0.74 0.07 -0.30 0.11 0.09 -0.08 0.50 -0.38 -1.49 -0.17
Total Depreciation and Amortization (D&A)		 0.01 0.01 0.01 0.00 0.21 0.26 0.41 0.84 0.02 0.45 0.29
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -15.68% -124.30% -134.22% -155.46% -204.35% -274.52% -190.69% -125.79% -181.89% -168.77%
Debt-free Net Working Capital to Revenue		 0.00% 85.35% -122.49% -77.67% -145.67% -194.82% -259.56% -171.11% -22.71% 144.04% -126.67%
Net Working Capital to Revenue		 0.00% 85.35% -132.85% -99.30% -170.51% -219.18% -259.56% -287.38% -44.13% 144.04% -126.67%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.65) ($52.20) $0.00 ($1.35) ($0.99) ($1.24) ($1.29) ($0.57) ($0.69) ($0.36) ($0.22)
Adjusted Weighted Average Basic Shares Outstanding		 1.06M 71.61K 1.65M 1.74M 2.01M 1.98M 4.59M 0.00 11.52M 10.07M 16.48M
Adjusted Diluted Earnings per Share		 ($1.65) ($52.20) $0.00 ($1.35) ($0.99) ($1.24) ($1.29) ($0.57) ($0.69) ($0.36) ($0.22)
Adjusted Weighted Average Diluted Shares Outstanding		 1.06M 71.61K 1.65M 1.74M 2.01M 1.98M 4.59M 9.98M 11.52M 10.07M 16.48M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($52.20) $0.00 $0.00 $0.00 ($1.24) $0.00 $0.00 $0.00 ($0.36) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.14M 0.00 1.65M 1.99M 2.49M 5.17M 11.03M 10.54M 13.91M 16.97M 17.17M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.26 -1.80 -1.66 -1.52 -1.23 -1.17 -3.20 -3.69 -5.28 -0.26 -2.19
Normalized NOPAT Margin		 -513.80% -735.61% -774.11% -930.39% -922.75% -1,115.82% -2,930.73% -2,193.78% -6,267.42% -272.80% -3,224.73%
Pre Tax Income Margin		 -733.99% -1,050.87% -1,105.87% -1,465.60% -1,499.38% -1,851.45% -4,427.47% -3,221.61% -9,043.49% -2,934.90% -5,014.65%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -9.74 -7.28 0.00 0.00 -35.76 -100.45 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 -6.82 -5.09 0.00 0.00 -25.03 -69.61 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -9.74 -7.28 0.00 0.00 -35.76 -100.45 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -6.82 -5.09 0.00 0.00 -25.03 -69.61 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Mangoceuticals’ financial statements continue to show a cash-burning, loss-making business, although some operating metrics have improved from the severe losses reported in mid-2025. The company generated $67,864 of revenue in Q1 2026, down 28% from $94,360 in Q4 2025 and 38% from $109,306 in Q1 2025. Reported gross profit was $29,001, representing a gross margin of approximately 43%.

Net loss attributable to common shareholders was $3.70 million, compared with a $3.65 million loss in Q4 2025 and a $5.13 million loss in Q1 2025. The company’s basic and diluted loss per share improved to $0.22 from $0.36 in Q4, but this was helped in part by a substantial increase in the weighted-average share count, which rose to 16.5 million from 10.1 million in Q4 2025.

Cash flow remains a significant concern. Mangoceuticals used $1.31 million in operating cash during Q1 2026, compared with $1.08 million in Q4 2025. With no equity, debt or other financing proceeds recorded during the quarter, cash and equivalents declined to just $174,562 at March 31, 2026, from $481,281 at September 30, 2025. At the current quarterly operating cash-burn rate, the company has limited liquidity without additional financing or a significant improvement in revenue and expenses.

  • Losses improved from Q1 2025: Net loss from continuing operations declined to $3.40 million from $4.84 million a year earlier, while operating loss improved from $4.58 million to $3.13 million.
  • Operating expenses declined year over year: Total operating expenses fell to $3.19 million in Q1 2026 from $4.66 million in Q1 2025. Selling, general and administrative expense also declined by approximately 32%.
  • Interest expense was eliminated in Q1 2026: The company reported no interest expense during the quarter, compared with $86,574 in Q4 2025 and $147,325 in Q2 2025.
  • Gross margin remains difficult to evaluate: Reported gross profit was positive in each of the recent quarters, but the statement data includes unusual cost-of-revenue values that do not consistently reconcile with revenue and gross profit. Investors should review the company’s filings for additional detail.
  • Amortization is a major noncash expense: Q1 2026 included $291,338 of amortization, and intangible assets totaled $13.94 million. This reduced accounting earnings but did not directly consume cash in the quarter.
  • Revenue momentum weakened: Q1 2026 revenue fell 28% sequentially and 38% year over year, reversing the improvement needed to support the company’s high operating-cost structure.
  • Operating cash flow remains consistently negative: Mangoceuticals has reported negative operating cash flow in every quarter provided, including $1.31 million of cash used in Q1 2026.
  • Liquidity is thin: Cash of $174,562 covered only a fraction of current liabilities of $737,606, producing a current ratio of roughly 0.29. The company may need to raise capital to fund ongoing operations.
  • Financing has been heavily dependent on equity issuance: The company raised common or preferred equity in multiple prior quarters, while the weighted-average share count increased from 1.6 million in Q1 2024 to 16.5 million in Q1 2026. Further fundraising could dilute existing shareholders.
  • Asset quality and accumulated losses are risks: Intangible assets represented approximately 97% of total assets at March 31, 2026, while retained earnings were negative $44.1 million. Future impairment charges or continued losses could further weaken shareholders’ equity.
07/29/26 12:16 AM ETAI Generated. May Contain Errors.

Mangoceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Mangoceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Mangoceuticals' net income appears to be on an upward trend, with a most recent value of -$20.64 million in 2025, rising from -$2.00 million in 2022. The previous period was -$8.71 million in 2024. View Mangoceuticals' forecast to see where analysts expect Mangoceuticals to go next.

Mangoceuticals' total operating income in 2025 was -$18.03 million, based on the following breakdown:
  • Total Gross Profit: $250.39 thousand
  • Total Operating Expenses: $18.21 million

Over the last 3 years, Mangoceuticals' total revenue changed from $8.94 thousand in 2022 to $456.02 thousand in 2025, a change of 5,001.5%.

Mangoceuticals' total liabilities were at $890.57 thousand at the end of 2025, a 37.5% decrease from 2024, and a 128.8% increase since 2022.

In the past 3 years, Mangoceuticals' cash and equivalents has ranged from $58.65 thousand in 2024 to $1.49 million in 2025, and is currently $1.49 million as of their latest financial filing in 2025.

Over the last 3 years, Mangoceuticals' book value per share changed from 0.06 in 2022 to 1.09 in 2025, a change of 1,820.9%.


Related Companies

Financial statements for NASDAQ:MGRX last updated on 7/28/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel